Cargando…
Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling
The present research aimed to characterize soft tissue implants that were prepared with the use of crosslinked hyaluronic acid (HA) using two different crosslinkers and multiple reagent concentrations, alone or in combination with fibrin. The effect of the implants was evaluated in an in vivo mouse...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396986/ https://www.ncbi.nlm.nih.gov/pubmed/35997457 http://dx.doi.org/10.3390/jfb13030119 |
_version_ | 1784772035442900992 |
---|---|
author | Hinsenkamp, Adél Fülöp, Ágnes Hricisák, László Pál, Éva Kun, Kiara Majer, Aliz Varga, Viktória Lacza, Zsombor Hornyák, István |
author_facet | Hinsenkamp, Adél Fülöp, Ágnes Hricisák, László Pál, Éva Kun, Kiara Majer, Aliz Varga, Viktória Lacza, Zsombor Hornyák, István |
author_sort | Hinsenkamp, Adél |
collection | PubMed |
description | The present research aimed to characterize soft tissue implants that were prepared with the use of crosslinked hyaluronic acid (HA) using two different crosslinkers and multiple reagent concentrations, alone or in combination with fibrin. The effect of the implants was evaluated in an in vivo mouse model, after 4 weeks in one group and after 12 weeks in the other. The explants were compared using analytical methods, evaluating microscopic images, and a histology analysis. The kinetics of the degradation and remodeling of explants were found to be greatly dependent on the concentration and type of crosslinker; generally, divinyl sulfone (DVS) resists degradation more effectively compared to butanediol diglycidyl ether (BDDE). The presence of fibrin enhances the formation of blood vessels, and the infiltration of cells and extracellular matrix. In summary, if the aim is to create a soft tissue implant with easier degradation of the HA content, then the use of 2–5% BDDE is found to be optimal. For a longer degradation time, 5% DVS is the more suitable crosslinker. The use of fibrin was found to support the biological process of remodeling, while keeping the advances of HA in void filling, enabling the parallel degradation and remodeling processes. |
format | Online Article Text |
id | pubmed-9396986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93969862022-08-24 Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling Hinsenkamp, Adél Fülöp, Ágnes Hricisák, László Pál, Éva Kun, Kiara Majer, Aliz Varga, Viktória Lacza, Zsombor Hornyák, István J Funct Biomater Article The present research aimed to characterize soft tissue implants that were prepared with the use of crosslinked hyaluronic acid (HA) using two different crosslinkers and multiple reagent concentrations, alone or in combination with fibrin. The effect of the implants was evaluated in an in vivo mouse model, after 4 weeks in one group and after 12 weeks in the other. The explants were compared using analytical methods, evaluating microscopic images, and a histology analysis. The kinetics of the degradation and remodeling of explants were found to be greatly dependent on the concentration and type of crosslinker; generally, divinyl sulfone (DVS) resists degradation more effectively compared to butanediol diglycidyl ether (BDDE). The presence of fibrin enhances the formation of blood vessels, and the infiltration of cells and extracellular matrix. In summary, if the aim is to create a soft tissue implant with easier degradation of the HA content, then the use of 2–5% BDDE is found to be optimal. For a longer degradation time, 5% DVS is the more suitable crosslinker. The use of fibrin was found to support the biological process of remodeling, while keeping the advances of HA in void filling, enabling the parallel degradation and remodeling processes. MDPI 2022-08-13 /pmc/articles/PMC9396986/ /pubmed/35997457 http://dx.doi.org/10.3390/jfb13030119 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hinsenkamp, Adél Fülöp, Ágnes Hricisák, László Pál, Éva Kun, Kiara Majer, Aliz Varga, Viktória Lacza, Zsombor Hornyák, István Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling |
title | Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling |
title_full | Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling |
title_fullStr | Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling |
title_full_unstemmed | Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling |
title_short | Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling |
title_sort | application of injectable, crosslinked, fibrin-containing hyaluronic acid scaffolds for in vivo remodeling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396986/ https://www.ncbi.nlm.nih.gov/pubmed/35997457 http://dx.doi.org/10.3390/jfb13030119 |
work_keys_str_mv | AT hinsenkampadel applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling AT fulopagnes applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling AT hricisaklaszlo applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling AT paleva applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling AT kunkiara applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling AT majeraliz applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling AT vargaviktoria applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling AT laczazsombor applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling AT hornyakistvan applicationofinjectablecrosslinkedfibrincontaininghyaluronicacidscaffoldsforinvivoremodeling |